Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

ClinicalTrials.gov ID: NCT04502693

Public ClinicalTrials.gov record NCT04502693. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.

Study identification

NCT ID
NCT04502693
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
3,657 participants

Conditions and interventions

Interventions

Combination Product · Biological

Eligibility (public fields only)

Age range
10 Years to 25 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 13, 2020
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022
Last update posted
Mar 4, 2024

2020 – 2022

United States locations

U.S. sites
64
U.S. states
24
U.S. cities
54
Facility City State ZIP Site status
GSK Investigational Site Chandler Arizona 85286
GSK Investigational Site Glendale Arizona 85308
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Bell Gardens California 90201
GSK Investigational Site Canoga Park California 91304
GSK Investigational Site Garden Grove California 92840
GSK Investigational Site Inglewood California 90301
GSK Investigational Site Los Gatos California 95032
GSK Investigational Site Cutler Bay Florida 33157
GSK Investigational Site Lake City Florida 32055
GSK Investigational Site Miami Florida 33126
GSK Investigational Site Miami Florida 33144
GSK Investigational Site Miami Florida 33165
GSK Investigational Site Miami Florida 33174
GSK Investigational Site Miami Florida 33186
GSK Investigational Site Orlando Florida 32801
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Orlando Florida 32808
GSK Investigational Site Oviedo Florida 32765
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Adairsville Georgia 30103
GSK Investigational Site Buford Georgia 30519
GSK Investigational Site Columbus Georgia 31904
GSK Investigational Site Hinesville Georgia 31313
GSK Investigational Site Nampa Idaho 83686
GSK Investigational Site Oak Brook Illinois 60523
GSK Investigational Site Wichita Kansas 67205
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Louisville Kentucky 40243
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Beverly Massachusetts 01915
GSK Investigational Site Fall River Massachusetts 02721
GSK Investigational Site Grosse Pointe Woods Michigan 48236
GSK Investigational Site Minneapolis Minnesota 55402
GSK Investigational Site Petal Mississippi 39465
GSK Investigational Site Missoula Montana 59804
GSK Investigational Site Missoula Montana 59808
GSK Investigational Site The Bronx New York 10455
GSK Investigational Site Dayton Ohio 45406
GSK Investigational Site Dayton Ohio 45419
GSK Investigational Site Grants Pass Oregon 97527
GSK Investigational Site Greenville South Carolina 29607
GSK Investigational Site North Charleston South Carolina 29405
GSK Investigational Site West Columbia South Carolina 29169
GSK Investigational Site Laredo Texas 78041
GSK Investigational Site Plano Texas 75024
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Kaysville Utah 84037
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Murray Utah 84107
GSK Investigational Site Orem Utah 84057
GSK Investigational Site Roy Utah 84067
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site South Jordan Utah 84095
GSK Investigational Site Syracuse Utah 84075
GSK Investigational Site Falls Church Virginia 22044
GSK Investigational Site Newport News Virginia 23606
GSK Investigational Site Richmond Virginia 23294
GSK Investigational Site Suffolk Virginia 23435
GSK Investigational Site Cheney Washington 99004
GSK Investigational Site Spokane Washington 99202
GSK Investigational Site Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04502693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2024 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04502693 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →